InCephalo
Key Facts
| Invested since | 2023 |
| Based in | International |
About the company
InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.
Do you want to
know more about this company?
InCephalo in the news
More startups from Life Sciences
Symphera is a Munich-based startup that is revolutionizing laparoscopic surgery with an innovative system designed to eliminate the need for manual instrument changes. Founded in 2023, Symphera was incubated at …
To the complete profileof Symphera
PerformaNat GmbH was founded in 2015 as a spin-off of the veterinary medicine department of the Freie Universität Berlin. The first product – an animal-feed additive for use with dairy …
To the complete profileof PerformaNat
Resolve Biosciences is creating solutions which offer the power of Molecular Cartography enabling scientists to gain valuable insights at subcellular resolution, across vast numbers of biomolecules (RNA, DNA, proteins) to …
To the complete profileof Resolve Biosciences
Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary …
To the complete profileof mbiomics
Exit
Capical is the world leading company for contact-free ECG-measurement via capacitive electrodes. The main application areas are drivers state monitoring for the automotive industry and contact-free cardiac monitoring solutions for …
To the complete profileof Capical
Nuuron was founded by Fabian Queisner and Dr. Markus Müschenich. The scientific director is Priv.-Doz. Dr. Julian Keil. The Nuuron team consists of experts in the fields of neuroscience, medicine, …
To the complete profileof Nuuron
IPO
Immunic Therapeutics is a clinical-stage biotech company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic, Inc. is headquartered in New York. …
To the complete profileof Immunic
Coramaze Technologies develops an innovative, highly differentiated, transcatheter tricuspid valve repair system, called TriPair. Headquartered in Germany with an R&D hub in Israel, we promote health equity by offering a …
To the complete profileof coramaze
Dimericon is a private biotech company focused on exploring the novel modality crosslinked helix dimers (Dimericons) to target hard-to-drug intracellular protein-protein interactions using rationally designed mimetics of helix dimers. The …
To the complete profileof Dimericon
MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®. Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases …
To the complete profileof MDTB Cell Manufacturing
Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system. Exit since July 2015.
To the complete profileof Provecs Medical
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a …
To the complete profileof Tubulis